Related Experiment Video

Updated: Jul 16, 2026

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

Adult sarcomas: a missed opportunity for sustained cooperative group translational and clinical research

Ernest C Borden1

  • 1Taussig Cancer Center Center for Hematology and Oncology Molecular Therapeutics, Cleveland Clinic Foundation, Cleveland, Ohio, USA.

Oncology (Williston Park, N.Y.)
|April 3, 2007
PubMed

Insights

The National Cancer Institute (NCI) funded the Intergroup Coalition Against Sarcomas (ICAS) to advance sarcoma research. However, NCI ended this initiative, hindering progress for adult sarcoma patients.

Area of Science:

  • Oncology
  • Sarcoma Research
  • Clinical Trials

Background:

  • Preclinical advances in sarcoma treatment offer future reductions in morbidity and mortality.
  • Limited institutional resources necessitate collaborative efforts for histology-specific research in adult sarcomas.

Purpose of the Study:

  • To establish a collaborative infrastructure for adult sarcoma research through the Intergroup Coalition Against Sarcomas (ICAS).
  • To secure National Cancer Institute (NCI) funding for histology-specific clinical and translational research.

Main Methods:

  • Leveraging the strengths of multimodality cooperative oncology groups.
  • Developing an infrastructure for broad investigator participation in protocol development and patient entry.

Main Results:

  • The ICAS initiative was developed with NCI funding and received excellent peer review evaluation.
  • The Division of Cancer Treatment of NCI terminated the ICAS initiative due to claimed insufficient funds.

Conclusions:

  • The termination of ICAS by NCI negatively impacts current and future adult sarcoma patients.
  • Lack of funding and collaborative infrastructure hinders critical research in adult sarcomas.

More Related Videos

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...